{
    "ticker": "ALEC",
    "name": "Alector, Inc.",
    "description": "Alector, Inc. is a biotechnology company focused on the discovery and development of immuno-neurology therapeutics for neurodegenerative diseases. Founded in 2013 and based in South San Francisco, California, Alector aims to harness the immune system to combat diseases such as Alzheimer\u2019s and other forms of dementia. The company\u2019s innovative approach is centered around the concept of enhancing the brain\u2019s immune response to restore neuronal function and prevent degeneration. Alector has developed a robust pipeline of product candidates, including monoclonal antibodies and immunotherapies designed to address the underlying causes of neurodegenerative diseases. With strong scientific backing and a commitment to transformative medicine, Alector collaborates with leading academic institutions and research organizations to advance its clinical programs. The company is dedicated to improving the lives of patients through groundbreaking research and development, with the goal of transforming how neurodegenerative diseases are treated. Alector is at the forefront of a new era in biological research, where understanding the immune system's role in neurological health is paramount.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2013",
    "website": "https://www.alector.com",
    "ceo": "Arnon Rosenthal",
    "social_media": {
        "twitter": "https://twitter.com/AlectorInc",
        "linkedin": "https://www.linkedin.com/company/alector-inc/"
    },
    "investor_relations": "https://investors.alector.com",
    "key_executives": [
        {
            "name": "Arnon Rosenthal",
            "position": "CEO"
        },
        {
            "name": "Eric L. Kandel",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Immuno-neurology Therapeutics",
            "products": [
                "AL001",
                "AL002",
                "AL003"
            ]
        }
    ],
    "seo": {
        "meta_title": "Alector, Inc. | Pioneering Immuno-neurology Therapeutics",
        "meta_description": "Alector, Inc. is a leading biotechnology company focused on developing immuno-neurology therapeutics for neurodegenerative diseases. Learn more about Alector's innovative approach and product pipeline.",
        "keywords": [
            "Alector",
            "Biotechnology",
            "Neurodegenerative Diseases",
            "Immunotherapy",
            "Alzheimer's Disease",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Alector known for?",
            "answer": "Alector is known for its focus on immuno-neurology therapeutics aimed at treating neurodegenerative diseases."
        },
        {
            "question": "Who is the CEO of Alector?",
            "answer": "Arnon Rosenthal is the CEO of Alector, Inc."
        },
        {
            "question": "Where is Alector headquartered?",
            "answer": "Alector is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Alector's main products?",
            "answer": "Alector's main products include AL001, AL002, and AL003, which are in various stages of clinical development."
        },
        {
            "question": "When was Alector founded?",
            "answer": "Alector was founded in 2013."
        }
    ],
    "competitors": [
        "BIIB",
        "AVXL",
        "SAVA",
        "ACAD"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "VRTX"
    ]
}